Study objective-The aim was to assess patients willingness to accept mortal risk in the drug treatment of chronic rheumatic disease.
Risk assessment of medicines can be divided into two separate tasks of risk estimation and risk evaluation.' The former utilises the available epidemiological data from clinical trials and postmarketing surveillance to determine the probability of a specific adverse drug reaction occurring in a particular patient population during a period of time. The latter is the judgemental process of balancing the therapeutic benefit of the drug against its estimated risk. The resolution of such "acceptable risk" decision problems in the management ofdrugs requires the decision makers-be they doctors, patients or regulators-to make a trade off, implicitly or explicitly, between risk and benefit.2 One experimental approach for eliciting risk-benefit preferences is the "standard gamble" method recently used in the evaluation of oral gold therapy for rheumatoid arthritis.3 The aim of the present study is to utilise this approach to examine patients' stated willingness to accept mortal drug risk to achieve a range ofhypothetical therapeutic benefits in the treatment oftwo chronic rheumatic diseases: (1) rheumatoid arthritis, the prototypic chronic inflammatory disease affecting primarily older women; (2) ankylosing spondylitis, also characterised by pain, inflammation, and stiffness but generally affecting a younger, more mobile, predominantly male population. Methods A sample of 100 consecutive in-and outpatients ( figure, where a person is confronted with two choices: Choice A (taking the drug) has two possible consequences, a probability 1-p that it will produce a specified health benefit (X) and a probability p that it will result in death (eg, 99% chance of cure, 1% chance of death). Choice B is not to take the drug and to remain in the current health state. The (ie, health benefit X in the figure) which was one of (a) total cure, (b) total relief of pain, (c) total relief of stiffness, (d) return to normal functioning.
HEALTH STATUS MEASURES
The Nottingham Health Profile is a widely used and well validated method of assessing health related quality of life.8 9 
Discussion
Deciding between the treatment options for chronic rheumatic disease requires a balancing of risk against benefit; the health gains from drug therapy may be palliative or disease modifying" but they are only achieved at the risk of adverse events, including death. If therapeutic decision making is to reflect patient preferences then clinicians require a greater understanding of the ways patients perceive and react to the potential risks and benefits of therapy. The experimental method ofthis study, using hypothetical scenarios and choices, is a useful framework for eliciting patient's views. The precise estimates of maximum acceptable risk responses should be viewed with caution; they are based on a small sample of patients from one tertiary referral centre, and extrapolation to other groups or inclusion in "real life" decisions would be unwise. Results are indicative and illustrative of the method, providing empirical markers for discussion and further study.
For this sample of patients with rheumatic disease, responses indicate that the average individual is prepared to accept a 1 in 5 chance of immediate death from a drug which offers a complete cure from the disease. Are such results reliable and valid? Although reliability in the form of within study reproducibility (ie, test -retest method) was not assessed in this study, the interstudy reproducibility of results for rheumatoid arthritis patients is encouraging; the 27% maximum acceptable risk for total cure from our 50 rheumatoid arthritis patients is identical to that found in an earlier US study of 247 rheumatoid arthritis patients using the standard gamble method. 3 Assessing the validity of expressed preferences for risk taking is more problematic because the "true" preferences that individuals hold cannot be directly observed, only indirectly revealed by the choice they make. While treatment risks in the order of 20% are commonly accepted for major acute interventions such as heart transplantation (80% survival at one year'2), similar risks for non-life-threatening diseases are not commonly observed, although there may be a willingness to accept increased mortal risk to achieve improvements in health related quality of life.'3 
